HETLIOZSolutions supports your patients

Vanda Pharmaceuticals is committed to helping your patients with Non-24

  • Live care coordinators can:
    • Answer questions about HETLIOZ® (tasimelteon) and Non-24
    • Provide benefits support
    • Connect patients with other resources for the totally blind
    • Guide patients through all available financial assistance options
      • Eligible patients may receive therapy with HETLIOZĀ® at little or no cost
    • Improve adherence through a comprehensive patient compliance program
    • Coordinate with specialty pharmacies to ensure delivery of medication
  • To begin the process of prescribing HETLIOZ®, which is only available through specialty pharmacies, download the Prescription & Service Request Form DOWNLOAD
  • To begin the process of prescribing HETLIOZ® to patients who receive Veterans Affairs (VA) Health Benefits, download the VA Intake Form DOWNLOAD

Patients can call HETLIOZSolutions™ at 1-844-HETLIOZ (1-844-438-5469)
to learn more

Important Safety Information

The most common adverse reactions (incidence >5% and at least twice as high on HETLIOZ® (tasimelteon) than on placebo) were headache, increased alanine aminotransferase, nightmares or unusual dreams, and upper respiratory or urinary tract infection. The risk of adverse reactions may be greater in elderly (>65 years) patients than younger patients because exposure to HETLIOZ® is increased by approximately 2-fold compared with younger patients.

Indication

HETLIOZ® is indicated for the treatment of Non-24-Hour Sleep-Wake Disorder (Non-24).

Important Safety Information

  • HETLIOZ® may cause somnolence: After taking HETLIOZ®, patients should limit their activity to preparing for going to bed, because HETLIOZ® can potentially impair the performance of activities requiring complete mental alertness.
  • The most common adverse reactions (incidence >5% and at least twice as high on HETLIOZ® than on placebo) were headache, increased alanine aminotransferase, nightmares or unusual dreams, and upper respiratory or urinary tract infection. The risk of adverse reactions may be greater in elderly (>65 years) patients than younger patients because exposure to HETLIOZ® is increased by approximately 2-fold compared with younger patients.
  • Use of HETLIOZ® should be avoided in combination with fluvoxamine or other strong CYP1A2 inhibitors, because of a potentially large increase in exposure of HETLIOZ®, and a greater risk of adverse reactions. HETLIOZ® should be avoided in combination with rifampin or other CYP3A4 inducers, because of a potentially large decrease in exposure of HETLIOZ®, with reduced efficacy.
  • There are no adequate and well-controlled studies of HETLIOZ® in pregnant women. Based on animal data, HETLIOZ® may cause fetal harm. HETLIOZ® should be used during pregnancy only if the potential benefit justifies the potential risks. Caution should be exercised when HETLIOZ® is administered to a nursing woman.
  • HETLIOZ® has not been studied in patients with severe hepatic impairment and is not recommended in these patients.
  • Safety and effectiveness of HETLIOZ® in pediatric patients have not been established.

Please see full Prescribing Information.